- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04342468
Blood Pressure Variability and Cardiovascular Disease Events in Patients With Hypertension (BPV)
Relationship of Blood Pressure Variability and Cardiovascular Disease Events Among Patients With Hypertension
Study Overview
Status
Intervention / Treatment
Detailed Description
This will be a cross-sectional study on patients with hypertension. The 10-year retrospective data on BP, treatment, biochemical changes, kidney function and CV events will be extracted from patient records.
Eligible patients who have given written informed consent will be given a questionnaire capturing data of their socio-demographic status, weight, height and BP measured.
Those agreeable to measure their own BP at home 3 times a day for a week will be loaned a BP device to measure their own BP at home. The home BP readings will be recorded onto a provided form and returned to the investigators.
Data will be analysed to
- determine BPV of the clinic visit-to-visit BPV (long tem BPV)
- determine the day to day BPV (short term BPV)
- examine the BPV to CV events, kidney function, cognition
- determine the prevalence of white coat and masked hypertension
- determine the level of control of BP
- examine the relationship of ownership of home BP devices to control and satisfaction of treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Federal Territory
-
Kuala Lumpur, Federal Territory, Malaysia, 59100
- University of Malaya Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All adult patients with hypertension on follow up at the primary care clinic of University of Malaya Medical Centre who fulfill the inclusion and exclusion criteria are eligible to be enrolled into the study
Eligible patients were recruited in a consecutive manner
Description
Inclusion Criteria:
- Patients on treatment for hypertension of at least 3 years
- Patients who consent to the study
Exclusion Criteria:
- those unable to give consent
- recent (less than 6 months) of cardiovascular events (stroke, heart attack, heart failure)
- patients on dialysis
- patients with end stage kidney failure
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The standard deviation value of blood pressure variability in treated hypertensive patients
Time Frame: 31 Dec 2020
|
The various indices of day-to-day and long term Blood pressure variability will be calculated giving the actual BPV (in absolute number ) in these patients
|
31 Dec 2020
|
|
Percentage of cardiovascular events in those with higher BPV compared to those with lower BPV
Time Frame: 31 Dec 2020
|
BPV will be categorized as above or below the mean BPV of the entire group.
The number of CV events in percentage in each group will be compared It is expected that those with higher BPV will have more CV events
|
31 Dec 2020
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Treated hypertensives with White Coat or Masked hypertension
Time Frame: 31 Dec 2020
|
The Home and Clinic BP measurements will be used to determine the percentage of Masked and White Coat Hypertension.
These two conditions are expected to be associated with more CV events than those with control of both clinic and home BP.
|
31 Dec 2020
|
|
Difference in cognition in those with higher BP variability compared to those with lower BPV
Time Frame: 31 Dec 2020
|
The Montreal Cognitive Assessment (MoCA) score will be compared between those with higher with those with lower BPV.
The minimum MoCA score is 0 and the maximum is 30.
A higher MoCA score indicates better cognition.
A MoCA score of 26 is considered as normal.
The MoCA score is expected to be lower in those with higher BPV.
|
31 Dec 2020
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Lai M Looi, MBBS FRCPath, University of Malaya Medical Centre
Publications and helpful links
General Publications
- Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010 Mar 13;375(9718):895-905. doi: 10.1016/S0140-6736(10)60308-X.
- Mancia G. Short- and long-term blood pressure variability: present and future. Hypertension. 2012 Aug;60(2):512-7. doi: 10.1161/HYPERTENSIONAHA.112.194340. Epub 2012 Jun 25. No abstract available.
- Muntner P, Joyce C, Levitan EB, Holt E, Shimbo D, Webber LS, Oparil S, Re R, Krousel-Wood M. Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care. J Hypertens. 2011 Dec;29(12):2332-8. doi: 10.1097/HJH.0b013e32834cf213.
- Rogers MA, Small D, Buchan DA, Butch CA, Stewart CM, Krenzer BE, Husovsky HL. Home monitoring service improves mean arterial pressure in patients with essential hypertension. A randomized, controlled trial. Ann Intern Med. 2001 Jun 5;134(11):1024-32. doi: 10.7326/0003-4819-134-11-200106050-00008.
- Chia YC, Ching SM, Lim HM. Visit-to-visit SBP variability and cardiovascular disease in a multiethnic primary care setting: 10-year retrospective cohort study. J Hypertens. 2017 May;35 Suppl 1:S50-S56. doi: 10.1097/HJH.0000000000001333.
- Chia YC, Lim HM, Ching SM. Long-Term Visit-to-Visit Blood Pressure Variability and Renal Function Decline in Patients With Hypertension Over 15 Years. J Am Heart Assoc. 2016 Nov 7;5(11):e003825. doi: 10.1161/JAHA.116.003825.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017314-5047
- WI207736 (OTHER_GRANT: Pfizer)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Hull University Teaching Hospitals NHS TrustNot yet recruitingCardiovascular Surgery | Cardiovascular Diseases (CVD)United Kingdom
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk FactorsUnited States
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Medical College of WisconsinNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
IRCCS Policlinico S. DonatoIRCCS San Raffaele; Fondazione Policlinico Universitario Agostino Gemelli IRCCS and other collaboratorsRecruitingCardiovascular Risk | Genetic Cardiovascular RiskItaly
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
Children's Hospital Medical Center, CincinnatiRecruitingCardiovascular Diseases (CVD)United States
Clinical Trials on non-interventional
-
Portsmouth Hospitals NHS TrustArdia Digital Health LtdNot yet recruitingChronic Kidney Disease
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)CompletedUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMCHIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related MalignancyUnited States, Puerto Rico
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
Ohio State University Comprehensive Cancer CenterCompletedHeavy Metal Exposure From VapingUnited States
-
Bristol-Myers SquibbWithdrawnNon-valvular Atrial FibrillationUnited States
-
Mayo ClinicRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterLilly FoundationRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Advanced Breast Carcinoma | Metastatic Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Enrolling by invitationBarrett Esophagus | Esophageal AdenocarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Merck Sharp & Dohme LLCRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Roswell Park Cancer InstituteRecruitingCigarette Smoking-Related CarcinomaUnited States